Development of an Efficient, Safe, and Environmentally Friendly

11 Mar 2016 - ... with an arylboronic acid using a low palladium catalyst loading, and the development of a controlled crystallization to provide the ...
0 downloads 0 Views 990KB Size
Subscriber access provided by NEW YORK UNIV

Full Paper

Development of an Efficient, Safe, and Environmentally Friendly Process for the Manufacture of GDC-0084 Andreas Stumpf, Andrew McClory, Herbert Yajima, Nathaniel Segraves, Remy Angelaud, and Francis Gosselin Org. Process Res. Dev., Just Accepted Manuscript • DOI: 10.1021/acs.oprd.6b00011 • Publication Date (Web): 11 Mar 2016 Downloaded from http://pubs.acs.org on March 12, 2016

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Organic Process Research & Development is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 30

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Organic Process Research & Development

Table of Contents Graphic

ACS Paragon Plus Environment

2

Organic Process Research & Development

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 2 of 30

KEYWORDS. Phase Transfer Catalysis. Annulation. Safety Calorimetry. Pd-Catalyzed SuzukiMiyaura Cross-Coupling. PMI Reduction. Purine.

ABSTRACT. An improved, efficient process with a significantly reduced process mass intensity (PMI) led to the multikilogram synthesis of a brain penetrant PI3K inhibitor GDC-0084. Highlights of the synthesis include a phase transfer catalyzed annulation in water, an efficient Suzuki-Miyaura cross-coupling of a chloropyrimidine with an arylboronic acid using a low palladium catalyst loading, and the development of a controlled crystallization to provide the API. The process delivered GDC-0084 with low levels of both impurities and residual metals.

ACS Paragon Plus Environment

3

Page 3 of 30

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Organic Process Research & Development

GDC-0084 (Figure 1)1, a potent and selective dual inhibitor of PI3K / mTOR with the ability to penetrate the blood-brain barrier, has been discovered in our laboratories for the treatment of various brain cancers.2 As part of the development program for this drug candidate, we required multikilogram amounts of API to support human clinical studies. Figure 1. Structure of GDC-0084 and ORTEP Representation O N N O

N

N N

N N

NH 2 !

GDC-0084

The discovery chemistry synthesis of GDC-0084 served as the starting point for the endeavor (Scheme 1). The route began with a selective THP protection of 2,6-dichloro-9H-purine 1, followed by a regioselective substitution with morpholine to give purine 3. Subsequent deprotonation with n-butyllithium3 and trapping with acetone furnished tertiary alcohol 4, which underwent an acid-mediated cleavage of the THP group to afford aminoalcohol 5. Alkylation with 2-bromoethyl acetate, followed by ester hydrolysis, then provided diol 6, which was subjected to a SN1 ring closure to furnish cyclic ether 7. Finally, a microwave-promoted Suzuki cross-coupling with pinacolboronate 8 produced GDC-0084.

ACS Paragon Plus Environment

4

Organic Process Research & Development

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 4 of 30

Scheme 1. Discovery Chemistry Synthesis of GDC-0084

At the outset we recognized that this route could be shortened by 2 steps if a direct annulation between aminoalcohol 5 and a suitable vicinal electrophile could be achieved to forge fused morpholine 7. Such a strategic change would also potentially lower the amount of an unproductive elimination side product formed in the SN1 cyclization (9, vide infra). Additionally, the use of chromatography at several steps, the presence of residual heavy metals in the API, and the need for a robust API crystallization process all needed to be addressed in the development of a scalable, phase-appropriate route to GDC-0084.

ACS Paragon Plus Environment

5

Page 5 of 30

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Organic Process Research & Development

First Generation Synthesis In order to accelerate the development timelines, compounds 5 and 84 were selected as starting materials and outsourced in advance of the first API batch. Compound 5 was manufactured on 30 kg scale in an overall yield of 91% and a purity of 99.5A% by HPLC. Each step of the proposed synthesis was then optimized in order to improve the yields and enable efficient access to GDC0084 with high purity. Stage 1: Annulation of Aminoalcohol 5 to Form Fused Morpholine 7 Our first objective was to establish a direct formation of fused morpholine 7 from aminoalcohol 5. Indeed, an initial screen of vicinal electrophiles5 identified 1,2-dibromoethane as a competent partner for annulation with 5 to construct alkylation product 7. The effect of solvent6 and base7 at 90 ºC8 were then examined in an effort to improve the conversion and minimize the formation of elimination product 9 (Table 1). Conversion was found to be highest in CH3CN and DMF (entries 1, 2, 5, and 6), with the latter solvent performing slightly better. Cesium carbonate (entry 1) and potassium carbonate (entry 5) were found to function similarly in terms of conversion, while the latter afforded a slightly lower amount of elimination side product 9. The reaction was observed to be exothermic, thus dose-control measures were investigated in order to mitigate the safety risk. Slow addition of 1,2-dibromoethane to a mixture of 5 and K2CO3 (entry 9) did not adversely affect the conversion but did lead to the formation of a new impurity, dimer 11, in 4A% (Figure 2). On the other hand, portion-wise addition of substrate 5 to a mixture of 1,2-dibromoethane and K2CO3 (entry 10) suppressed the formation of 11 to